Etidronic acid
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Etidronic acid
| |
| Systematic (IUPAC) name | |
| (1-hydroxy-1-phosphono-ethyl)phosphonic acid | |
| Identifiers | |
| CAS number | |
| ATC code | M05 M05BB01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C2H8O7P2 |
| Mol. mass | 206.028 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 3% |
| Metabolism | Nil |
| Half life | 1 to 6 hours |
| Excretion | Renal and fecal |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
C(US) |
| Legal status |
℞ Prescription only |
| Routes | Oral, intravenous |
|
WikiDoc Resources for Etidronic acid | |
|
Articles | |
|---|---|
|
Most recent articles on Etidronic acid Most cited articles on Etidronic acid | |
|
Media | |
|
Powerpoint slides on Etidronic acid | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Etidronic acid at Clinical Trials.gov Trial results on Etidronic acid Clinical Trials on Etidronic acid at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Etidronic acid NICE Guidance on Etidronic acid
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Etidronic acid Discussion groups on Etidronic acid Patient Handouts on Etidronic acid Directions to Hospitals Treating Etidronic acid Risk calculators and risk factors for Etidronic acid
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Etidronic acid | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Etidronic acid (INN) or etidronate disodium (trade name Didronel®) is a bisphosphonate used to strengthen bone, treat osteoporosis, and treat Paget's disease of bone.
Chelating Agent and Anti-oxidant
Etidronic acid is a chelating agent and may be added to bind or, to some extent, counter the effects of substances, such as arsenic, iron, or other metal ions (that can occur in the presence of some soaps), which may be discharged as a component of grey wastewater and could conceivably contaminate groundwater supplies. Etidronic acid also acts to retard rancidification and oxidation of fatty acids. While etidronic acid has not been limited from inclusion in cosmetics and does have legitimate uses, it is recommended that, as with most cosmetic products (particularly soaps), the product should be thoroughly rinsed from the skin after use.
Etidronic acid is listed as an ingredient of several cosmetic formulations. Several examples of Etidronic acid's presence in soap products are: Propolis soap, Dove body wash, Axe body wash, Lever 2000 body wash, Yardley of London, Johnson and Johnson's Lavender, Chamomile Creamy Baby Soap bar and Tesco Pure Soap bar.
Etidronic acid is also included among swimming pool chemicals. It is used as a stain inhibitor to prevent metal ions coming out of solution and staining the sides of swimming pools.
Drugs for treatment of bone diseases (M05) | |
|---|---|
| Bisphosphonates | Nitrogenous (Pamidronic acid, Alendronic acid, Ibandronic acid, Risedronic acid, Zoledronic acid) - Non-nitrogenous (Etidronic acid, Clodronic acid, Tiludronic acid) |
| Bone morphogenetic proteins | Dibotermin alfa - Eptotermin alfa |
| Other | Ipriflavone - Aluminium chlorohydrate - Strontium ranelate |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
